These new agents, along with Rho-associated kinase (ROCK)2 inhibitors like KD025, which modulate inflammatory responses by targeting Th17 cells, represent a significant leap forward in psoriasis therapeutics (Zanin-Zhorov et al. 2017). Here, ROCK2 is linked to psoriasis.